11/24
04:05 pm
ctnm
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
Medium
Report
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
11/24
09:44 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Robert W. Baird from $16.00 to $14.00. They now have an "outperform" rating on the stock.
Low
Report
Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Robert W. Baird from $16.00 to $14.00. They now have an "outperform" rating on the stock.
11/21
09:47 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $22.00. They now have an "outperform" rating on the stock.
Low
Report
Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $22.00. They now have an "outperform" rating on the stock.
11/21
09:19 am
ctnm
Contineum falls after missing main goals in multiple sclerosis trial [Seeking Alpha]
Low
Report
Contineum falls after missing main goals in multiple sclerosis trial [Seeking Alpha]
11/20
04:30 pm
ctnm
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) [Yahoo! Finance]
High
Report
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) [Yahoo! Finance]
11/20
04:05 pm
ctnm
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
High
Report
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
11/13
09:53 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $22.00 price target on the stock.
Medium
Report
Contineum Therapeutics (NASDAQ:CTNM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $22.00 price target on the stock.
11/8
01:13 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at
Wall St
Medium
Report
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at
Wall St
10/30
05:26 pm
ctnm
Contineum Therapeutics GAAP EPS of -$0.45 [Seeking Alpha]
Low
Report
Contineum Therapeutics GAAP EPS of -$0.45 [Seeking Alpha]
10/30
04:05 pm
ctnm
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Medium
Report
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
9/30
08:40 am
ctnm
Here's Why We're Not Too Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation [Yahoo! Finance]
9/26
06:54 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
9/25
08:06 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $20.00 price target on the stock.
Medium
Report
Contineum Therapeutics (NASDAQ:CTNM) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $20.00 price target on the stock.
9/18
08:05 am
ctnm
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Neutral
Report
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791